MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ero.2026.01.004

Медицинская библиотека · EULAR rheumatology open · 2026

Low value of routine serological screening for hepatitis B in patients with rheumatoid arthritis starting rituximab therapy in a nonendemic region.

Bovens Pauline M, Wientjes Maike Hm, den Broeder Nathan, Ten Cate David F, van der Maas Aatke, den Broeder Alfons A

СтатьяПеревод в очереди

Аннотация

OBJECTIVES

Rituximab (RTX) is an effective and safe treatment for rheumatoid arthritis (RA), but is associated with an increased risk of reactivation of hepatitis B virus (HBV) infection. Therefore, (inter)national guidelines recommend HBV screening prior to initiation of RTX treatment. However, the incidence of HBV in RA patients in nonendemic areas is expected to be very low, with known suboptimal screening adherence. This study aims to assess the added diagnostic value of routine serological HBV screening in RA patients initiating RTX.

METHODS

This retrospective single-centre cohort study included all patients with a clinical diagnosis of RA intending to initiate RTX between April 2012 and April 2024. Data on patient and disease characteristics, HBV screening results, and additional laboratory results were collected. Adherence to HBV screening, proportion of positive test results (hepatitis B surface antigen or core antibody positive), and incidence of HBV reactivation were assessed.

RESULTS

Of 975 included patients, 270 (28 %) were serologically screened for HBV. Six of those (2.2 %) had a positive screening result, of whom 3 eventually did not receive RTX. All 6 had a known HBV history or risk factor. No active HBV infections were observed after initiating RTX (mean follow-up 6.97 years), regardless of screening.

CONCLUSIONS

Routine serological HBV screening identified very few previously unrecognised infections, and-in spite of screening adherence being low-no HBV reactivations occurred. Routine serological HBV screening, therefore, seems redundant in a low-risk population and should be reserved for patients with known risk factors.

Для цитирования: Bovens Pauline M, Wientjes Maike Hm, den Broeder Nathan, Ten Cate David F, van der Maas Aatke, den Broeder Alfons A. Low value of routine serological screening for hepatitis B in patients with rheumatoid arthritis starting rituximab therapy in a nonendemic region.. EULAR rheumatology open. 2026. DOI: 10.1016/j.ero.2026.01.004.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.